Compare KPTI & STIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KPTI | STIM |
|---|---|---|
| Founded | 2008 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.6M | 105.5M |
| IPO Year | 2013 | 2018 |
| Metric | KPTI | STIM |
|---|---|---|
| Price | $5.43 | $1.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $15.33 | $3.00 |
| AVG Volume (30 Days) | 1.2M | ★ 1.5M |
| Earning Date | 05-11-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.25 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $146,067,000.00 | $52,776,000.00 |
| Revenue This Year | N/A | $11.51 |
| Revenue Next Year | $46.62 | $11.63 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $3.51 | $0.80 |
| 52 Week High | $10.99 | $4.84 |
| Indicator | KPTI | STIM |
|---|---|---|
| Relative Strength Index (RSI) | 30.03 | 46.33 |
| Support Level | $3.93 | $1.22 |
| Resistance Level | $6.96 | $1.46 |
| Average True Range (ATR) | 0.88 | 0.18 |
| MACD | -0.39 | 0.01 |
| Stochastic Oscillator | 11.14 | 62.35 |
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.